These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 39307765)
21. [Guidelines for economic evaluation of post-marketing Chinese patent medicine]. Shi LW; Xie YM; Nie XY; Han S; Tian X; Wang ZF Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1129-1136. PubMed ID: 38621920 [TBL] [Abstract][Full Text] [Related]
22. Improving the Safety of Medicines in the European Union: From Signals to Action. Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897 [TBL] [Abstract][Full Text] [Related]
23. [Guideline for clinical comprehensive evaluation of Chinese patent medicine (2022 version)]. Yuan WA; Zhang JH; Liu JP; Yang ZQ; Cao JL; Liao X; Xi XY; Han M; Li WY; Qiu ZW; Feng SY; Guo YY; Cao LJ; Liao XH; Ai YL; Huang J; Jia LL; Su XF; Wu X; Dai ZQ; Guo JH; Lu BQ; Zhang XX; Tang JY Zhongguo Zhong Yao Za Zhi; 2023 Jan; 48(1):256-264. PubMed ID: 36725278 [TBL] [Abstract][Full Text] [Related]
24. Recent advances in Chinese patent medicines entering the international market. Zhang B; Pei W; Cai P; Wang Z; Qi F Drug Discov Ther; 2022 Dec; 16(6):258-272. PubMed ID: 36543180 [TBL] [Abstract][Full Text] [Related]
25. Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: current status and future perspective. Zhang L; Yan J; Liu X; Ye Z; Yang X; Meyboom R; Chan K; Shaw D; Duez P J Ethnopharmacol; 2012 Apr; 140(3):519-25. PubMed ID: 22374080 [TBL] [Abstract][Full Text] [Related]
26. [Construction of model for multidimensional evaluation of value and risk of Chinese patent medicine]. Li G; Li ZK; Yang HJ; Zhan ZL; Li HM; Tang SH Zhongguo Zhong Yao Za Zhi; 2021 Mar; 46(5):1284-1292. PubMed ID: 33787124 [TBL] [Abstract][Full Text] [Related]
27. Clinical practice guideline on treating influenza in adult patients with Chinese patent medicines. Wu L; Chen Y; Ma Y; Yang Z; Yang N; Deng W; Chen Y; Sun Y; Li Y; Lin L Pharmacol Res; 2020 Oct; 160():105101. PubMed ID: 32739428 [TBL] [Abstract][Full Text] [Related]
28. [Reporting standards for expert consensus on clinical practice of Chinese patent medicines of China Association of Chinese Medicine]. Mo M; Liao X; Zhang XX; Li B; Chen W; Zhao GZ; Guo YB Zhongguo Zhong Yao Za Zhi; 2019 Jun; 44(12):2644-2651. PubMed ID: 31359735 [TBL] [Abstract][Full Text] [Related]
29. [Evidence map analysis of randomized controlled trial of commonly used Chinese patent medicines in treatment of type 2 diabetes mellitus in recent five years]. Jiang JJ; Jing YY; Li YY; Yang YN; Liao X; Xie YM Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1102-1112. PubMed ID: 38621917 [TBL] [Abstract][Full Text] [Related]
30. [Analysis and reflection on current situation of Chinese patent medicine for children in China]. Liu H; Chen YJ; Fu QF; Zhao SY; Nie LH; Ma R; Rong P Zhongguo Zhong Yao Za Zhi; 2024 Apr; 49(7):1966-1973. PubMed ID: 38812209 [TBL] [Abstract][Full Text] [Related]
31. EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection. Postigo R; Brosch S; Slattery J; van Haren A; Dogné JM; Kurz X; Candore G; Domergue F; Arlett P Drug Saf; 2018 Jul; 41(7):665-675. PubMed ID: 29520645 [TBL] [Abstract][Full Text] [Related]
32. [Summary and analysis of safety warning on clinical application of anti-cold Chinese patent medicine preparations]. Lai XX; Lin H; Luo YN; Wang YY; Duan XH; Wang L; Luo R; Chen YH Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(8):1594-600. PubMed ID: 26281605 [TBL] [Abstract][Full Text] [Related]
33. An overview on adverse drug reactions to traditional Chinese medicines. Chan K; Zhang H; Lin ZX Br J Clin Pharmacol; 2015 Oct; 80(4):834-43. PubMed ID: 25619530 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of Chinese patent medicine in the adjuvant treatment of prostate cancer: A Bayesian network meta-analysis. Wang S; Zhang F; Liu J; Qin P Medicine (Baltimore); 2024 Mar; 103(12):e37180. PubMed ID: 38517994 [TBL] [Abstract][Full Text] [Related]
35. [Network Meta-analysis of 11 Chinese patent medicines in treatment of dilated cardiomyopathy]. Wang ZX; Wang H; Ban JF; Zhou YB; Qie R Zhongguo Zhong Yao Za Zhi; 2023 Dec; 48(24):6778-6797. PubMed ID: 38212037 [TBL] [Abstract][Full Text] [Related]
36. [Network Meta-analysis of Chinese patent medicines in treatment of liver stagnation and spleen deficiency of depression]. Yu Y; Zhang G; Han T; Li J; Huang HL Zhongguo Zhong Yao Za Zhi; 2019 Dec; 44(23):5217-5224. PubMed ID: 32237360 [TBL] [Abstract][Full Text] [Related]
37. Comparison of efficacy and safety of traditional Chinese patent medicines for diabetic nephropathy: A protocol for Bayesian network meta-analysis. Liu S; Li A; Jiang B; Mi J; Nan H; Bao P; Nan Z Medicine (Baltimore); 2022 May; 101(19):e29152. PubMed ID: 35583526 [TBL] [Abstract][Full Text] [Related]
38. [Evidence mapping of clinical research on 28 Chinese patent medicines for tension-type headache]. Guan YY; Yu XY; Li CY; Shu JZ; Tao WQ; Mi XJ; Luo XQ; Lian ZY; Zhao YH; Tang J; Liao X Zhongguo Zhong Yao Za Zhi; 2021 Dec; 46(24):6558-6567. PubMed ID: 34994149 [TBL] [Abstract][Full Text] [Related]
39. [Exploration and practice of post-marketing survival benefit evaluation of Chinese patent medicine for cancer]. Xu BW; Wu JY; Li J; Zhang Y; Cao LC; Zhang XX; Gao RK Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1980-1987. PubMed ID: 33982508 [TBL] [Abstract][Full Text] [Related]
40. [Reevaluation on adverse reaction monitoring and safety of proprietary Chinese medicines of Chongqing from 2005 to 2011]. Yang YY; Dong Z; Zhu SB; Sun HF; Yang MP Zhongguo Zhong Yao Za Zhi; 2012 Dec; 37(23):3659-63. PubMed ID: 23477159 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]